Zepbound, from drugmaker Eli Lilly, is already approved for people who are obese or overweight and have a related health condition, such as type 2 diabetes, high cholesterol or high blood ...
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...
Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...
Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...
The pharmaceutical industry faces significant challenges as Novo Nordisk and Eli Lilly grapple with trial setbacks and market ...
A breast cancer diagnosis is almost always followed by invasive biopsies, surgery, radiotherapy, chemotherapy and hormone ...
Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs market. Merck on Dec. 16 said it had just ...
"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity." ...
Mindy McCormick, 67, read that her insurer would soon stop covering the weight loss drug Wegovy, which she had been taking for more than two years. Nearly 9,000 people across the state had received ...
Detailed price information for Berkshire Hathaway Cl B (BRK-B-N) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback